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2. X-ray screening, and
3. Two week run-in period
Telephone screening was comprehensive and included questions on age,
seafood allergies, co-morbidities (RA, bilateral knee replacements, unstable
diabetes, recent lower limb surgery or intra-articular injections), intention
to undergo joint replacement in next year, opioid use, informed that knee
is ‘bone-on-bone’, willingness to be randomised, willingness to adhere to
study procedures and level of knee pain ‘at its worst’ in the past week.
The subsequent radiographic screening required evidence of predominant
medial tibio-femoral joint disease but retaining at least 2 mm of medial
joint space width in a suﬃciently symptomatic (≥4 out of 10) knee. If still
eligible, a two week ‘run-in’ period required adherence to study treatment
capsules and return of a completed Participant Diary.
Results: From an initial 2,682 telephone enquiries, 605 people were
randomised (October 2007-2009). The main barrier to recruitment was
unwillingness to be randomised to placebo (Figure 1).
Figure 1. Recruitment ﬂowchart.
Fifty percent of the radiographic ineligibility was due to complete loss of
medial tibio-femoral joint space. A further 13% withdrew from participation
during the ‘run-in’ period. The baseline demographics of the LEGS study
cohort (Table1) demonstrate the required screening pain of ≥4 out of 10
was not maintained at the subsequent baseline assessment (WOMAC) or
7-day Participant Diary by many participant.
Table 1. Baseline demographics
N=605 n, % Pain and disability Mean (sd)
Age mean (sd) 60.3 (8.2) WOMAC pain (0-100) 33.2 (17.6)
BMI mean (sd) 28.9 (5.8) WOMAC function (0-100) 32.4 (18.2)
Female 339, 56% SF-12 PCS 41.3 (9.5)
Obese 214, 35% SF-12 MCS 52.8 (10.0)
No comorbidity 73, 12% Mean pain over 7-days (0-10) 3.5 (1.8)
High blood pressure 195, 32% Max pain over 7-days (0-10) 4.6 (2.1)
Back pain 138, 23%
Stomach problems 67, 11%
Depression 62, 10%
Heart Disease 55, 9%
Diabetes 35, 6%
Paracetamol for knee pain 211, 35%
NSAIDs for knee pain 119, 20%
Conclusions: A comprehensive telephone screening reduced the burden
of radiographic screenings. The two week ’run- in’ of study procedures
further reduced the number of participants likely to drop out soon after
randomisation. It is diﬃcult to identify people with knee osteoarthritis that
have at least moderate ongoing pain, yet retain medial tibio-femoral joint
space width >2mm.
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Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are the “Gold
Standards” in the treatments of various pain and inﬂammation related dis-
orders like arthritis. However, their oral administration and use of newer
selective COX-2 NSAIDs known to induce severe intolerance in patients.
Thus, the present work aims to compare the eﬃcacy and safety of a
epicutaneously applied diclofenac in novel liposomal gel vis-à-vis marketed
gel and placebo for relief of signs and symptoms in osteoarthritis (OA) of
knee.
Methods: This was a randomized, double-blind, controlled trial on 36 pa-
tients with knee osteoarthritis. They were randomly assigned to liposomal
gel, marketed gel and placebo, twice a day for 6 weeks. The patients
were assessed by primary eﬃcacy outcome measures included the changes
from baseline to end of study on the WOMAC (Western Ontario McMaster
Universities) Osteoarthritis Index. The radiographic imaging of OA in the
knee was also performed for Kellgren-Lawrence criteria. Safety of the gel
was also assessed by evaluating adverse events, vital signs, and irritation at
the application site.
Results: In liposomal gel treated group, the pain, stiffness and diﬃculty
performing routine activities showed statistically signiﬁcantly improve-
ments on 6 weeks of treatment compared to the other tested gels. While,
all the treatments were found to be well tolerated with no observed
adverse event.
Conclusions: Diclofenac in liposomal gel is superior to other tested formu-
lations viz. marketed gel and placebo in the relieving the symptoms of OA
of the knee. Hence, it can be concluded that diclofenac in liposomal gel can
be a rational alternative to oral diclofenac formulations for management of
various pain and inﬂammation related ailments including osteoarthritis.
Epidemiology & Health Services Research
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OSTEOARTHRITIS DUE TO SURGERY FOR KNEE INJURY IN YOUNGER
ADULTS
E. Badley, M. Canizares, A. Davis
Univ. Hlth.Networks, Toronto, ON, Canada
Purpose: The literature suggests ACL injuries and meniscal lesions are
associated with the development of knee osteoarthritis (OA). There is
limited evidence that surgical repair of these lesions diminishes future
development of knee OA. A review of the long-term consequences of these
injuries suggests that some 50% of those undergoing meniscectomy will
develop OA between10 to 20 years after the surgery. Estimates from the
literature indicate that 10% to 90% of individuals with ACL injury develop
OA within 10 to 20 years of the lesion. This raises the question as to
what proportion of all knee OA cases might be associated with previous
arthroscopic surgery.
Methods: A study to estimate the proportion of individuals who will
develop OA after having arthroscopic surgery was designed by juxtaposing
data form different sources. (a) Data on the age- and sex-speciﬁc rates of
arthroscopic surgery (closed repair of the knee which includes menisec-
tomy and ACL repairs) in Ontario, Canada for the population aged 5-45
years, (b) data on the age and sex incidence of OA estimated from physician
billing data in British Columbia, Canada, (c) Population data for Canada,
and d) estimates of the proportion of individuals with arthroscopic surgery
who develop OA were combined to calculate estimates of the number of
incident OA cases likely due to arthroscopic surgery at the end of a 10 year
period. The rates of arthroscopic surgery were applied to the population to
estimate the number of individuals with this type of surgery. OA incidence
rates were also applied to the population to estimate the number of new
OA cases every year. The following scenarios for the proportion developing
OA over a period of 10 years were used: 10%, 20%, 30% and 40%. The main
assumptions made were: constant arthroscopic rates and incidence rates of
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Scenarios (Proportion developing OA Number of new OA cases likely Number of new OA cases likely Proportion of all new cases
after arthroscopic surgery) due to arthroscopic surgery due to arthroscopic surgery aged 5-54 “due to” arthroscopy
(5-54 years) (all ages) (proportion of new cases - all ages)
10% 2265 6267 1.9% (1.4%)
20% 4531 12534 3.9% (2.9%)
30% 6796 18801 5.8% (4.3%)
40% 9062 25068 7.8% (5.8%)
OA over time, and a linear risk of developing OA after having arthroscopic
surgery.
Results: Examination of arthroscopic rates showed no signiﬁcant ﬂuctu-
ation from 2000 to 2007. Overall, the rate of arthroscopic knee surgery
was 188 per 100,000 population in Ontario, 127 per 100,000 for ages 5-44
years. Men aged 5 to 44 years had twice as many surgeries as women
the same age (166/100,000 persons and 88/100,000 persons respectively).
Rates increased with increasing age peaking in the 45-54 years age group
in men and in the 54-64 years age group in women. The ﬁndings from
applying the rates for those aged 5 to 44 years at surgery to the population
and the four scenarios for the proportion developing OA over 10 years are
shown in the table below.
Conclusions: A calculation juxtaposing different sources of data suggests
that arthroscopic surgery associated with knee injury likely accounts for
between 1.9% and 7.8% of new cases of OA in the younger population and
between 1.4% and 5.8% of all cases. Given population rates of arthroscopic
surgery and assuming outcomes similar to those reported in the literature,
this simple estimation highlights the importance of injury prevention
particularly in relation to OA in the younger population.
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Purpose: Osteoarthritis (OA) is a heterogeneous disease that is prevalent
in hands. Different subsets within hand OA, such as nodular hand OA and
erosive hand OA (EOA), are recognized. EOA is a subset, deﬁned as having
erosions in interphalangeal joints on radiographs, that is suggested to have
an aggressive clinical course. No clear data about prevalence and clinical
burden of EOA are available. This study assesses the prevalences of erosive
hand OA in the general population and symptomatic hand OA, and its
relation to hand pain and disability.
Methods: Cross-sectional data of participants from a population based
study (age ≥ 55 years) in the Rotterdam area were used. Radiographs of
the hands were scored previously by the Kellgren-Lawrence (K/L) scoring
method. In the present study, erosive lesions (deﬁned as an erosive or
remodeled phase) in the distal, proximal and thumb interphalangeal joints
(DIPJs, PIPJs and IPJs) were scored according by the Verbruggen-Veys
scoring method. Radiographic hand OA was deﬁned as the presence of K/L
grade ≥ 2 in two out of three groups of hand joints (DIPJs/IPJs, PIPJs and
ﬁrst carpometacarpal joint (1st CMCJs)) of each hand. Symptomatic hand
OA was deﬁned as hand pain and presence of criteria for radiographic hand
OA. Hand pain was assessed by a standard question by trained interviewers.
Hand disability was measured by 8 hand questions in the Stanford Health
Assessment Questionnaire (HAQ). A mean HAQ-score of ≥ 0.5 was classiﬁed
as disability.
Point prevalence was calculated as to divide the number of subjects with
one erosive lesion by the total population. Multivariate logistic regression
analyses were used to estimate the effect of erosive hand OA on pain
and disability between erosive and non-erosive patients. Results were
presented as odds ratios (OR) with a 95% conﬁdence interval (95%CI),
adjusted for age and sex.
Results: Of the 3459 participants, 56% was female, with a mean age (SD)
of 66 years (7.0) and mean Body Mass Index (SD) of 26.3 (3.6) kg/m2.
Radiographic hand OA was seen in 27% (n=941) and symptomatic hand
OA in 6% (n=207). One erosion only was seen in 96 subjects and minimal
two erosions or more were seen in 44 persons (46% of erosive patients).
The overall prevalence of EOA in the general population was 2.8% and in
individuals with symptomatic hand OA 15.8%. Presence of erosive hand OA
led to an adjusted OR for pain of 3.6 (95%CI 2.4-5.6) and for disability 2.4
(95% CI 1.1-5.4) in the general population.
In subjects with radiographic hand OA, participants with erosion were
more likely to experience hand pain (adjusted OR 3.1, 95%CI 1.9-5.2) and
more likely to report hand disability (adjusted OR 3.1, 95%CI 1.3-7.6). A
dose-response relationship between the number of erosions per participant
and presence of pain was seen. If participants had two or more joints with
erosions, they were ﬁve times more likely to have pain in their hands than
individuals without erosions in the general population (adjusted OR 5.3,
95%CI 2.9-9.9).
Conclusions: The prevalence of erosive hand osteoarthritis is 2.8% in the
general population and rises to 15.8% in individuals with symptomatic
hand OA. It has a substantial impact on clinical burden. Further studies
should focus on treatment options for this hand OA subset.
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Purpose: Older age, presence of comorbidities and adverse effects of anal-
gesics have been suggested to contribute to an excess mortality in patients
with osteoarthritis, but available data are limited. Therefore, we examined
determinants of mortality in a large population based cohort of patients
with osteoarthritis of the knee or hip.
Methods: We analysed all-cause and disease-speciﬁc mortality over a
median of 14 years in 1163 patients with symptomatic and radiologically
conﬁrmed osteoarthritis of the knee or hip from the population-based
Somerset and Avon Survey of Health (SASH) using mortality data from
Characteristic Hazard ratio P-value
(95% conﬁdence interval)
Age at baseline <0.001
35 to 54 years 1.00 (reference)
55 to 74 years 12.1 (5.38 to 27.4)
≥75 years 40.7 (17.7 to 93.5)
Male gender 1.56 (1.27 to 1.90) <0.001
Lower social class 1.13 (0.93 to 1.38) 0.21
Smoking at baseline 1.26 (0.97 to 1.63) 0.08
Type of osteoarthritis 0.66
Knee only 1.00 (reference)
Hip only 1.12 (0.87 to 1.45)
Knee and hip 1.08 (0.86 to 1.35)
Previous joint replacement 1.16 (0.83 to 1.61) 0.38
Obesity 0.84 (0.67 to 1.05) 0.13
COPD 1.20 (0.93 to 1.55) 0.16
Diabetes 1.97 (1.33 to 2.93) 0.001
Depression 0.95 (0.68 to 1.34) 0.79
Arterial hypertension 1.14 (0.92 to 1.40) 0.24
Cancer 2.32 (1.53 to 3.52) <0.001
Chronic inﬂammatory disease 1.01 (0.83 to 1.24) 0.91
Eye disease 1.07 (0.81 to 1.42) 0.65
Cardiovascular disease 1.40 (1.14 to 1.73) 0.002
Knee or hip pain 0.90 (0.73 to 1.10) 0.30
Walking disability 1.53 (1.23 to 1.91) <0.001
